JP2022527542A5 - - Google Patents

Info

Publication number
JP2022527542A5
JP2022527542A5 JP2021558985A JP2021558985A JP2022527542A5 JP 2022527542 A5 JP2022527542 A5 JP 2022527542A5 JP 2021558985 A JP2021558985 A JP 2021558985A JP 2021558985 A JP2021558985 A JP 2021558985A JP 2022527542 A5 JP2022527542 A5 JP 2022527542A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
composition according
ifn
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021558985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527542A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/053221 external-priority patent/WO2020202106A1/en
Publication of JP2022527542A publication Critical patent/JP2022527542A/ja
Publication of JP2022527542A5 publication Critical patent/JP2022527542A5/ja
Priority to JP2024152418A priority Critical patent/JP2025000638A/ja
Pending legal-status Critical Current

Links

JP2021558985A 2019-04-04 2020-04-03 抗IFN-α/ω抗体の投与方法 Pending JP2022527542A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024152418A JP2025000638A (ja) 2019-04-04 2024-09-04 抗IFN-α/ω抗体の投与方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962829317P 2019-04-04 2019-04-04
US62/829,317 2019-04-04
PCT/IB2020/053221 WO2020202106A1 (en) 2019-04-04 2020-04-03 Method of administration of an anti-ifn-alpha/-omega antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024152418A Division JP2025000638A (ja) 2019-04-04 2024-09-04 抗IFN-α/ω抗体の投与方法

Publications (2)

Publication Number Publication Date
JP2022527542A JP2022527542A (ja) 2022-06-02
JP2022527542A5 true JP2022527542A5 (cg-RX-API-DMAC7.html) 2023-03-27

Family

ID=72662887

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558985A Pending JP2022527542A (ja) 2019-04-04 2020-04-03 抗IFN-α/ω抗体の投与方法
JP2024152418A Pending JP2025000638A (ja) 2019-04-04 2024-09-04 抗IFN-α/ω抗体の投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024152418A Pending JP2025000638A (ja) 2019-04-04 2024-09-04 抗IFN-α/ω抗体の投与方法

Country Status (5)

Country Link
US (2) US12202892B2 (cg-RX-API-DMAC7.html)
EP (1) EP3947448A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022527542A (cg-RX-API-DMAC7.html)
MA (1) MA55559A (cg-RX-API-DMAC7.html)
WO (1) WO2020202106A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117102A1 (en) 2018-10-26 2020-04-30 Janssen Biotech, Inc. Type i interferon signatures and methods of use
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0490233A1 (de) * 1986-03-10 1992-06-17 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Monoclonale Antikörper gegen BgIII-Hybridinterferone, deren Verwendung und Verfahren zu ihrer Herstellung
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
EP1851248B1 (en) 2005-02-10 2016-08-10 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
ES2549903T3 (es) 2008-05-07 2015-11-03 Argos Therapeutics, Inc. Anticuerpos humanizados contra interferón alfa humano
RU2013157177A (ru) * 2011-05-25 2015-06-27 МЕДИММЬЮН, ЭлЭлСи Способы лечения системной красной волчанки, склеродермии и миозита
TWI713453B (zh) * 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗il12/il23抗體治療狼瘡之安全且有效之方法

Similar Documents

Publication Publication Date Title
CN1214043C (zh) 抗γ-干扰素的人化抗体
JP2025172841A5 (cg-RX-API-DMAC7.html)
US8178092B2 (en) Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
JP2023548858A5 (cg-RX-API-DMAC7.html)
US12565526B2 (en) Formulations of anti-RSV antibodies and methods of use thereof
EP3360896B1 (en) Antibody to hepatitis b surface antigen and use thereof
JP2021533204A5 (cg-RX-API-DMAC7.html)
JP2018515493A5 (cg-RX-API-DMAC7.html)
KR20150038227A (ko) 건선의 치료방법
US20230049011A1 (en) Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
WO2025223497A1 (zh) 一种稳定的抗人IL-4Rα单克隆抗体制剂
JP2024511853A5 (cg-RX-API-DMAC7.html)
JP2022534494A5 (cg-RX-API-DMAC7.html)
KR20250173550A (ko) 자가면역 용혈성 빈혈(aiha) 치료를 위한 방법 및 조성물
JP2022530063A (ja) 抗体製剤
JP2025526370A (ja) 免疫グロブリン様転写物7(ilt7)結合タンパク質を含む製剤
TW202302147A (zh) 使用抗baffr抗體治療狼瘡腎炎
WO2021018191A1 (zh) Il-17拮抗剂治疗自身免疫疾病的方法
TW201309329A (zh) 結合人類il-12之人類抗體及其用途
CN116685351A (zh) Empacta的结果:一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究
US20250230238A1 (en) Methods and compositions for treating systemic lupus erythematous (sle)
JP2022502380A5 (cg-RX-API-DMAC7.html)
CA3115708C (en) Formulations of anti-rsv antibodies and methods of use thereof
EP4334351A1 (en) Treatment for systemic lupus erythematosus using anti-baffr antibodies
WO2025188845A1 (en) STABLE FORMULATIONS FOR TNFα ANTIBODIES AND USES THEREOF